Physician profile
Matthew D Barb
NPI 1366426157
$670.34
in general payments reported to CMS, 2019-2025
16 companies · $23.85 in 2025
The $23.85 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $61.75 · 2022: $226 · 2023: $148 · 2024: $70.57 · 2025: $23.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $147.75 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $123.49 | 2022-2024 | Vraylar |
| Pfizer INC. | $59.10 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.67 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.03 | 2024-2025 | Caplyta |
| Amgen INC. | $35.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $32.99 | 2020-2023 | |
| Myriad Women'S Health, INC. | $31.64 | 2023 | Myrisk |
| Corium, LLC | $26.34 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $23.65 | 2022 | |
| Lilly USA, LLC | $21.67 | 2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $17.03 | 2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.15 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2019 | |
| Merck Sharp & Dohme LLC | $11.54 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Barb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.